5-fluorouracil (5-FU) plus leucovorin (LV) therapy is the most widely used regimen with a high evidence as the first-line treatment for advanced colorectal cancer (CRC), as well as CPT-11 as the second-line. Recently, it is reported in several randomized prospective studies that convenient oral combination of UFT and LV has equal efficacy and less adverse effect. Intrahepatic arterial infusion (IHA) therapy shows high response rate in the treatment of liver metastasis. Survival benefit of IHA has to be disclosed by further clinical trials. Prospective studies showed that 6 months' administration of 5-FU and LV after curative resection of Dukes' C CRC contributes to a patients' better survival.